Omalizumab versus Usual Care: Results from a Naturalistic Longitudinal Study in Routine Care
Author:
Publisher
S. Karger AG
Subject
Immunology,General Medicine,Immunology and Allergy
Reference23 articles.
1. Predicting and evaluating response to omalizumab in patients with severe allergic asthma
2. The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update
3. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma
4. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Validity and Responsiveness of EQ-5D in Asthma: A Systematic Review and Meta-analysis;The Patient - Patient-Centered Outcomes Research;2024-09-07
2. A systematic literature review of burden of illness in adults with uncontrolled moderate/severe asthma;Respiratory Medicine;2022-01
3. Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies;The Journal of Allergy and Clinical Immunology: In Practice;2021-01
4. ‘Real-world’ effectiveness of omalizumab in adults with severe allergic asthma: a meta-analysis;Expert Review of Clinical Immunology;2020-12-14
5. Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018;Expert Review of Clinical Immunology;2019-02-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3